Michael S. Wyzga - 08 Feb 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Director
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
08 Feb 2024
Transactions value $
$0
Form type
4
Filing time
09 Feb 2024, 16:15:20
Previous filing
02 Jan 2024
Next filing
11 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +45K $0.00 45K 08 Feb 2024 American Depository Shares 45K $3.87 Direct F1, F2
transaction MREO Deferred Restricted Stock Units Award +30.8K 30.8K 08 Feb 2024 American Depository Shares 30.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date.
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3 Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.